- Home
- PHAT vs NEO Comparison
PHAT vs NEO Comparison
Compare PHAT & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- NEO
- Stock Information
- Founded
- PHAT 2018
- NEO 2001
- Country
- PHAT United States
- NEO United States
- Employees
- PHAT N/A
- NEO N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- NEO Precision Instruments
- Sector
- PHAT Health Care
- NEO Health Care
- Exchange
- PHAT Nasdaq
- NEO Nasdaq
- Market Cap
- PHAT 640.9M
- NEO 625.2M
- IPO Year
- PHAT 2019
- NEO 1999
- Fundamental
- Price
- PHAT $8.35
- NEO $5.16
- Analyst Decision
- PHAT Strong Buy
- NEO Buy
- Analyst Count
- PHAT 5
- NEO 8
- Target Price
- PHAT $16.40
- NEO $12.14
- AVG Volume (30 Days)
- PHAT 937.1K
- NEO 2.7M
- Earning Date
- PHAT 08-07-2025
- NEO 07-29-2025
- Dividend Yield
- PHAT N/A
- NEO N/A
- EPS Growth
- PHAT N/A
- NEO N/A
- EPS
- PHAT N/A
- NEO N/A
- Revenue
- PHAT $81,859,000.00
- NEO $689,189,000.00
- Revenue This Year
- PHAT $195.03
- NEO $13.83
- Revenue Next Year
- PHAT $106.77
- NEO $11.35
- P/E Ratio
- PHAT N/A
- NEO N/A
- Revenue Growth
- PHAT 3055.70
- NEO 9.70
- 52 Week Low
- PHAT $2.21
- NEO $4.72
- 52 Week High
- PHAT $19.71
- NEO $19.12
- Technical
- Relative Strength Index (RSI)
- PHAT 47.45
- NEO 29.52
- Support Level
- PHAT $7.61
- NEO $4.81
- Resistance Level
- PHAT $9.23
- NEO $6.61
- Average True Range (ATR)
- PHAT 0.66
- NEO 0.40
- MACD
- PHAT -0.08
- NEO -0.17
- Stochastic Oscillator
- PHAT 30.64
- NEO 17.46
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.